Felix Cleemann

USPTO Granted Patents = 23 (Patent Applications = 23)

CIPO Patents = 9 (Patent Applications = 4)

EPO Patents = 8 (Patent Applications = 19)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 155(Granted Patents)

Location History:

Heidelberg, DE (2014 - 2016)
Mainz, DE (2020 - 2024)

Company Filing History:

9 out of 12

Ascendis Pharma Growth Disorders A/s

patents

8 out of 10

Ascendis Pharma Bone Diseases A/s

patents

4 out of 1,829

Sanofi-a Ventis Deutschland Gmbh

Years Active: 2014-2025

Loading Chart...

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12453778 - Incremental dose finding in controlled-release PTH compounds (2025-10-28),

2. 12403182 - Liquid pharmaceutical formulations of PTH conjugates (2025-09-02),

3. 12239689 - Controlled-release CNP agonists with low initial NPR-B activity (2025-03-04),

4. 12214020 - PTH prodrugs (2025-02-04),

5. 12156917 - CNP prodrugs with carrier attachment at the ring moiety (2024-12-03),

6. 12083182 - Controlled-release CNP agonists with increased NEP stability (2024-09-10),

7. 11918628 - Controlled-release PTH compound (2024-03-05),

8. 11890326 - Controlled-release PTH compound (2024-02-06),

9. 11857603 - PTH compounds with low peak-to-trough ratios (2024-01-02),

10. 11793861 - PTH prodrugs (2023-10-24),

11. 11759504 - PTH compounds with low peak-to-trough ratios (2023-09-19),

12. 11633487 - Prodrugs comprising an aminoalkyl glycine linker (2023-04-25),

13. 11413351 - CNP prodrugs with carrier attachment at the ring moiety (2022-08-16),

14. 11389511 - Controlled-release CNP agonists with reduced side-effects (2022-07-19),

15. 11389510 - Controlled-release CNP agonists with low initial NPR-B activity (2022-07-19),

Title: Felix Cleemann: Innovator in Controlled-Release Therapeutics

Introduction: Felix Cleemann, based in Mainz, Germany, is a prominent inventor in the field of pharmaceuticals, holding an impressive portfolio of 21 patents. His work primarily focuses on controlled-release therapeutic agents, contributing valuable advancements to medical science.

Latest Patents: Among his notable inventions, Cleemann has developed a groundbreaking patent for Controlled-release CNP agonists with low initial NPR-B activity. This inventive solution describes a controlled-release CNP agonist that releases its active components with a half-life of at least 6 hours under physiological conditions. Remarkably, this controlled-release formulation demonstrates a higher biological efficacy, with an EC that is at least 20-fold greater than that of the corresponding free CNP agonist, while the released CNP agonist has an EC that is at most 3-fold higher. In addition, he has patented PTH prodrugs, which encompass pharmaceutical compositions featuring these prodrugs and their therapeutic applications.

Career Highlights: Felix Cleemann has made significant contributions during his tenure at major pharmaceutical companies, including Ascendis Pharma Growth Disorders and Ascendis Pharma Bone Diseases. His innovative mindset has propelled his career forward, allowing him to claim multiple patents reflecting his expertise in drug development.

Collaborations: Throughout his career, Cleemann has collaborated with esteemed colleagues, including Harald Rau and Ulrich Hersel. Their joint efforts in pharmaceutical research have led to advancements in therapeutic solutions and increased the impact of their work in the field.

Conclusion: With a remarkable track record of 21 patents and a focus on pharmaceutical innovations, Felix Cleemann stands out as a key contributor in controlled-release therapeutics. His groundbreaking inventions and collaborations continue to influence the landscape of medicinal science, promising improved treatment options for various health conditions.

This text is generated by artificial intelligence and may not be accurate.